Individualized support and training for young people at risk for psychosis
Individualized Vocational and Educational Support and Training for Clinical High Risk for Psychosis (InVEST)
NA · Beth Israel Deaconess Medical Center · NCT05114733
This study is testing a special support program for young people at risk of psychosis to see if it helps them with their education and job skills better than waiting for treatment.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 24 (estimated) |
| Ages | 12 Years to 22 Years |
| Sex | All |
| Sponsor | Beth Israel Deaconess Medical Center (other) |
| Locations | 1 site (Boston, Massachusetts) |
| Trial ID | NCT05114733 on ClinicalTrials.gov |
What this trial studies
This study tests the InVEST program, which provides individualized vocational and educational support for young individuals identified as being at clinical high risk for psychosis. The research is divided into two parts: an open trial to gather feasibility and acceptability data, followed by a randomized controlled trial comparing InVEST with a delayed treatment group. The intervention targets cognitive, emotional, and behavioral mechanisms contributing to functional impairment in this population. The study aims to refine the intervention based on participant feedback and assess its preliminary efficacy.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 12-22 who meet criteria for clinical high risk for psychosis and exhibit mild role functioning impairment.
Not a fit: Patients who have previously met diagnostic criteria for full psychosis will not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could improve role functioning and overall quality of life for young individuals at risk for psychosis.
How similar studies have performed: While the specific approach of InVEST is novel, early intervention strategies for psychosis risk have shown promise in other studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion: 1. age 12-22, 2. can speak English, 3. meet broad CHR-P criteria based on the Structured Interview for Psychosis Risk Syndromes (SIPS), 4. shows at least mild role functioning impairment on the Global Functioning-Role scale (GF:R), 5. parent is willing to provide permission (and client is willing to assent) for invest coaches to communicate with treatment providers. Exclusion: 1. Previously met diagnostic criteria for full psychosis on the Structured Interview for Psychosis Risk Syndromes. 2. Does not meet inclusion criteria listed above.
Where this trial is running
Boston, Massachusetts
- Beth Israel Deaconess Medical Center/ Massachusetts Mental Health Center — Boston, Massachusetts, United States (RECRUITING)
Study contacts
- Principal investigator: Michelle Friedman-Yakoobian, PHD — Department of Psychiatry at BIDMC - a major teaching hospital of Harvard Medical School
- Study coordinator: Michelle Friedman-Yakoobian
- Email: mfriedm3@bidmc.harvard.edu
- Phone: 617-754-1210
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Clinical High Risk for Psychosis, clinical high risk for psychosis, psychosis risk syndrome, school functioning, intervention